Țară: Statele Unite ale Americii
Limbă: engleză
Sursă: NLM (National Library of Medicine)
ISOSORBIDE MONONITRATE (UNII: LX1OH63030) (ISOSORBIDE MONONITRATE - UNII:LX1OH63030)
Lannett Company, Inc.
ISOSORBIDE MONONITRATE
ISOSORBIDE MONONITRATE 30 mg
ORAL
PRESCRIPTION DRUG
Isosorbide Mononitrate Extended-Release Tablets are indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. Isosorbide Mononitrate Extended-Release Tablets are contraindicated in patients who have shown hypersensitivity or idiosyncratic reactions to other nitrates or nitrites.
Isosorbide Mononitrate Extended-Release Tablets, USP 30 mg are white, capsule-shaped tablets scored on one side and engraved "KU 128" on the unscored side. They are supplied as follows: Bottles of 90 NDC 62175-128-46 Bottles of 100 NDC 62175-128-37 Bottles of 500 NDC 62175-128-41 Bottles of 1000 NDC 62175-128-43 Isosorbide Mononitrate Extended-Release Tablets, USP 60 mg are white, capsule-shaped tablets scored on one side and engraved "KU 119" on the unscored side. They are supplied as follows: Bottles of 90 NDC 62175-119-46 Bottles of 100 NDC 62175-119-37 Bottles of 500 NDC 62175-119-41 Bottles of 1000 NDC 62175-119-43 Isosorbide Mononitrate Extended-Release Tablets, USP 120 mg are white, capsule-shaped tablets engraved "KU 129" on one side. They are supplied as follows: Bottles of 100 NDC 62175-129-37 Bottles of 1000 NDC 62175-129-43 Store at 20°-30°C (68°-86°F) [See USP]. Distributed by: Lannett Company, Inc. Philadelphia, PA 19136 CIA71195F Rev. 02/19
Abbreviated New Drug Application
ISOSORBIDE MONONITRATE- ISOSORBIDE MONONITRATE TABLET, EXTENDED RELEASE LANNETT COMPANY, INC. ---------- ISOSORBIDE MONONITRATE EXTENDED-RELEASE TABLETS, USP RX ONLY DESCRIPTION Isosorbide mononitrate (ISMN), an organic nitrate and the major biologically active metabolite of isosorbide dinitrate (ISDN), is a vasodilator with effects on both arteries and veins. Each tablet, for oral administration, contains either 30 mg, 60 mg or 120 mg of isosorbide mononitrate in an extended-release formulation. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, hydrogenated castor oil, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose and talc. The molecular formula of ISMN is C H NO and the molecular weight is 191.14. The chemical name for ISMN is 1,4:3,6-dianhydro-,D-glucitol 5-nitrate; the compound has the following structural formula: ISMN is a white, crystalline, odorless compound which is stable in air and in solution, has a melting point of about 90°C, and an optical rotation of +144° (2% in water, 20°C). Isosorbide mononitrate is freely soluble in water, ethanol, methanol, chloroform, ethyl acetate, and dichloromethane. CLINICAL PHARMACOLOGY MECHANISM OF ACTION The Isosorbide Mononitrate Extended-Release Tablet, USP is an oral extended-release formulation of ISMN, the major active metabolite of isosorbide dinitrate; most of the clinical activity of the dinitrate is attributable to the mononitrate. The principal pharmacological action of ISMN and all organic nitrates in general is relaxation of vascular smooth muscle, producing dilatation of peripheral arteries and veins, especially the latter. Dilatation of the veins promotes peripheral pooling of blood, decreases venous return to the heart, thereby reducing left ventricular end-diastolic pressure and pulmonary capillary wedge pressure (preload). Arteriolar relaxation reduces systemic vascular resistance, systolic arterial pressure and mean arterial pressure (afterload). Dilatation of the c Citiți documentul complet